{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:02:18Z","timestamp":1784890938845,"version":"3.55.0"},"reference-count":31,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Obstetrics and Gynaecology"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/01443615.2026.2700014","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:32:31Z","timestamp":1784889151000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Re-evaluating low-molecular-weight heparin use in recurrent missed miscarriage: current evidence and future directions"],"prefix":"10.1080","volume":"46","author":[{"given":"Jaiden","family":"Townsend","sequence":"first","affiliation":[{"name":"Kettering General Hospital","place":["Kettering, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Attala","sequence":"additional","affiliation":[{"name":"East and North Hertfordshire NHS Trust","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-022-03365-4"},{"issue":"1","key":"e_1_3_2_3_1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1186\/s12884-021-04161-1","article-title":"Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study","volume":"21","author":"Bai W.","year":"2021","unstructured":"Bai, W., et al., 2021. Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study. BMC Pregnancy and Childbirth, 21 (1), 683.","journal-title":"BMC Pregnancy and Childbirth"},{"key":"e_1_3_2_4_1","doi-asserted-by":"crossref","first-page":"940644","DOI":"10.3389\/fmed.2022.940644","article-title":"Pharmacokinetic data in pregnancy: a review of available literature data and important considerations in collecting clinical data","volume":"9","author":"Coppola P.","year":"2022","unstructured":"Coppola, P., et al., 2022. Pharmacokinetic data in pregnancy: a review of available literature data and important considerations in collecting clinical data. Frontiers in Medicine, 9, 940644.","journal-title":"Frontiers in Medicine"},{"issue":"7","key":"e_1_3_2_5_1","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004734.pub4","article-title":"Aspirin and\/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia","volume":"2014","author":"De Jong P.G.","year":"2014","unstructured":"De Jong, P.G., et al., 2014. Aspirin and\/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database of Systematic Reviews, 2014 (7), CD004734.","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"e_1_3_2_6_1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1055\/s-0031-1293207","article-title":"Testing for inherited thrombophilia in recurrent miscarriage","volume":"29","author":"de Jong P.G.","year":"2011","unstructured":"de Jong, P.G., Goddijn, M. and Middeldorp, S., 2011. Testing for inherited thrombophilia in recurrent miscarriage. Seminars in Reproductive Medicine, 29 (6), 540\u2013547.","journal-title":"Seminars in Reproductive Medicine"},{"issue":"11","key":"e_1_3_2_7_1","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis","volume":"18","author":"Devreese K.M.","year":"2020","unstructured":"Devreese, K.M., et al., 2020. Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis: JTH, 18 (11), 2828\u20132839.","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1515\/jbcpp-2021-0312"},{"issue":"2","key":"e_1_3_2_9_1","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002859.pub2","article-title":"Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant","volume":"2012","author":"Empson M.B.","year":"2005","unstructured":"Empson, M.B., et al., 2005. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database of Systematic Reviews, 2012 (2), CD002859.","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"e_1_3_2_10_1","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Garcia D.A.","year":"2012","unstructured":"Garcia, D.A., et al., 2012. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 141 (2 Suppl), e24S\u2013e43S.","journal-title":"Chest"},{"issue":"5","key":"e_1_3_2_11_1","first-page":"807","article-title":"Heparin and low-molecular-weight heparin","volume":"99","author":"Gray E.","year":"2008","unstructured":"Gray, E., Mulloy, B. and Barrowcliffe, T.W., 2008. Heparin and low-molecular-weight heparin. Thrombosis and Haemostasis, 99 (5), 807\u2013818.","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0626"},{"key":"e_1_3_2_13_1","first-page":"1","article-title":"Reducing the risk of venous thromboembolism during pregnancy and the puerperium","volume":"37","author":"Gynaecologists R.","year":"2015","unstructured":"Gynaecologists, R., 2015. Reducing the risk of venous thromboembolism during pregnancy and the puerperium. Green-Top Guideline, 37, 1.","journal-title":"Green-Top Guideline,"},{"issue":"5","key":"e_1_3_2_14_1","article-title":"Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss","author":"Hamuly\u00e1k E.N.","year":"2020","unstructured":"Hamuly\u00e1k, E.N., et al., 2020. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database of Systematic Reviews, (5), CD012852.","journal-title":"Cochrane Database of Systematic Reviews,"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.3_suppl.188S"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60010156"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000641"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0007-1323.2001.01800.x"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/00033197221126244"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.003198"},{"issue":"10395","key":"e_1_3_2_21_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0140-6736(23)00693-1","article-title":"Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial","volume":"402","author":"Quenby S.","year":"2023","unstructured":"Quenby, S., et al., 2023. Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial. The Lancet, 402 (10395), 54\u201361.","journal-title":"The Lancet"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60793-5"},{"key":"e_1_3_2_23_1","volume-title":"Recurrent miscarriage: Green-top Guideline No. 17.","author":"Royal College of Obstetricians and Gynaecologists (RCOG)","year":"2023","unstructured":"Royal College of Obstetricians and Gynaecologists (RCOG) 2023. Recurrent miscarriage: Green-top Guideline No. 17. London: RCOG. Available from: https:\/\/www.rcog.org.uk\/guidance (Accessed 10 August 2025)."},{"issue":"1","key":"e_1_3_2_24_1","doi-asserted-by":"crossref","first-page":"031","DOI":"10.1055\/s-2000-9497","article-title":"Comparative pharmacokinetics of LMWHs","volume":"26","author":"Samama M.M.","year":"2000","unstructured":"Samama, M.M. and Gerotziafas, G.T., 2000. Comparative pharmacokinetics of LMWHs. Seminars in Thrombosis and Hemostasis, 26 (Number s1), 031\u2013038. Copyright\u00a9 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.:+ 1 (212) 584-4662.","journal-title":"Seminars in Thrombosis and Hemostasis"},{"issue":"3","key":"e_1_3_2_25_1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1067\/mcp.2002.127114","article-title":"The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers","volume":"72","author":"Sanderink G.J.","year":"2002","unstructured":"Sanderink, G.J., et al., 2002. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clinical Pharmacology and Therapeutics, 72 (3), 308\u2013318.","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"3","key":"e_1_3_2_26_1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0049-3848(02)00031-2","article-title":"Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment","volume":"105","author":"Sanderink G.J.C.","year":"2002","unstructured":"Sanderink, G.J.C., et al., 2002. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thrombosis Research, 105 (3), 225\u2013231.","journal-title":"Thrombosis Research"},{"issue":"2","key":"e_1_3_2_27_1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.36518\/2689-0216.1464","article-title":"Anti-factor Xa level monitoring for enoxaparin prophylaxis and treatment in high-risk patient groups","volume":"4","author":"Sikes L.","year":"2023","unstructured":"Sikes, L., et al., 2023. Anti-factor Xa level monitoring for enoxaparin prophylaxis and treatment in high-risk patient groups. HCA Healthcare Journal of Medicine, 4 (2), 105\u2013109.","journal-title":"HCA Healthcare Journal of Medicine"},{"key":"e_1_3_2_28_1","article-title":"ESHRE guideline: recurrent pregnancy loss\u2014update 2022","author":"The Eshre Guideline Group On R.P.L.","year":"2023","unstructured":"The Eshre Guideline Group On R.P.L., et al., 2023. ESHRE guideline: recurrent pregnancy loss\u2014update 2022. Human Reproduction Open, (1), hoad002. Available from: https:\/\/www.eshre.eu\/guidelines (Accessed 10 August 2025).","journal-title":"Human Reproduction Open,"},{"issue":"1","key":"e_1_3_2_29_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/humupd\/dmu049","article-title":"Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment","volume":"21","author":"Tong M.","year":"2015","unstructured":"Tong, M., Viall, C.A. and Chamley, L.W., 2015. Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment. Human Reproduction Update, 21 (1), 97\u2013118.","journal-title":"Human Reproduction Update"},{"issue":"4","key":"e_1_3_2_30_1","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/jcpt.13169","article-title":"The effect of anti\u2010Xa monitoring on the safety and efficacy of low\u2010molecular\u2010weight heparin anticoagulation therapy: a systematic review and meta\u2010analysis","volume":"45","author":"Wu T.","year":"2020","unstructured":"Wu, T., et al., 2020. The effect of anti\u2010Xa monitoring on the safety and efficacy of low\u2010molecular\u2010weight heparin anticoagulation therapy: a systematic review and meta\u2010analysis. Journal of Clinical Pharmacy and Therapeutics, 45 (4), 602\u2013608.","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"6","key":"e_1_3_2_31_1","article-title":"Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy","author":"Yaakob C.A.C.","year":"2010","unstructured":"Yaakob, C.A.C., et al., 2010. Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy. Cochrane Database of Systematic Reviews, (6)","journal-title":"Cochrane Database of Systematic Reviews,"},{"issue":"6","key":"e_1_3_2_32_1","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/AOG.0b013e3181deba40","article-title":"Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis","volume":"115","author":"Ziakas P.D.","year":"2010","unstructured":"Ziakas, P.D., Pavlou, M. and Voulgarelis, M., 2010. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstetrics and Gynecology, 115 (6), 1256\u20131262.","journal-title":"Obstetrics and Gynecology"}],"container-title":["Journal of Obstetrics and Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/01443615.2026.2700014","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/01443615.2026.2700014","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/01443615.2026.2700014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:32:34Z","timestamp":1784889154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/01443615.2026.2700014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/01443615.2026.2700014"],"URL":"https:\/\/doi.org\/10.1080\/01443615.2026.2700014","relation":{},"ISSN":["0144-3615","1364-6893"],"issn-type":[{"value":"0144-3615","type":"print"},{"value":"1364-6893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijog20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijog20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2700014"}}